ANXA5 and myelodysplastic syndrome: Connor et al. (2013) evaluated the reactivity of thrombocytes and PMPs (displaying positivity for annexin V and CD41) concentrations in patients with malignant (myelodysplastic syndromes and ET) and non-malignant (immune thrombocytopenia) hematological disorders.